FDA inspection
Able Laboratories Inc.: FDA inspection ending Feb 4, 2004
FDA inspection 310872 · Official Action Indicated (OAI) · S Plainfield, NJ
Key facts
| Inspection ID | 310872 |
|---|---|
| Firm | Able Laboratories Inc. |
| FEI number | 2245394 |
| Address | 6 Hollywood Ct |
| City | S Plainfield |
| State | NJ |
| ZIP | 07080-4204 |
| Fiscal year | 2004 |
| Inspection end date | Feb 4, 2004 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
| Warning letter | UCM146349 |
At a glance
- None Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data